On the public citation graph

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation

https://doi.org/10.1128/aac.02467-19
0 signed · 61 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/978-3-540-77349-8_23openalex-snapshot
Manifestations of Human Cytomegalovirus Infection: Proposed Mechanisms of Acute and Chronic Disease
inferredcites →https://doi.org/10.1007/s00430-007-0066-xopenalex-snapshot
The history of cytomegalovirus and its diseases
inferredcites →https://doi.org/10.1016/j.beha.2008.10.002openalex-snapshot
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?
inferredcites →https://doi.org/10.1016/j.beha.2011.06.003openalex-snapshot
Adoptive immunotherapy with virus-specific T cells
inferredcites →https://doi.org/10.1016/j.hemonc.2017.05.001openalex-snapshot
Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation
inferredcites →https://doi.org/10.1016/j.hoc.2010.11.011openalex-snapshot
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
inferredcites →https://doi.org/10.1016/j.idc.2010.01.008openalex-snapshot
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
inferredcites →https://doi.org/10.1016/s2352-3026(15)00289-6openalex-snapshot
Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
inferredcites →https://doi.org/10.1038/bmt.2016.141openalex-snapshot
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
inferredcites →https://doi.org/10.1038/nri.2016.38openalex-snapshot
T cell responses to cytomegalovirus
inferredcites →https://doi.org/10.1038/sj.bmt.1703382openalex-snapshot
Is there an upper age limit for bone marrow transplantation?
inferredcites →https://doi.org/10.1056/nejmoa1303688openalex-snapshot
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
inferredcites →https://doi.org/10.1056/nejmoa1309533openalex-snapshot
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
inferredcites →https://doi.org/10.1056/nejmoa1310214openalex-snapshot
A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
inferredcites →https://doi.org/10.1056/nejmoa1706640openalex-snapshot
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
inferredcites →https://doi.org/10.1080/14712598.2017.1369949openalex-snapshot
In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation
inferredcites →https://doi.org/10.1086/339329openalex-snapshot
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
inferredcites →https://doi.org/10.1128/aac.00382-16openalex-snapshot
In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539
inferredcites →https://doi.org/10.1128/aac.01794-16openalex-snapshot
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
inferredcites →https://doi.org/10.1128/aac.02698-15openalex-snapshot
A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers
inferredcites →https://doi.org/10.1182/blood-2008-10-143560openalex-snapshot
How we treat cytomegalovirus in hematopoietic cell transplant recipients
inferredcites →https://doi.org/10.1200/jco.2008.17.6545openalex-snapshot
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
inferredcites →https://doi.org/10.12659/aot.902805openalex-snapshot
Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program
inferredcites →https://doi.org/10.1371/journal.pone.0059863openalex-snapshot
Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection
inferredcites →https://doi.org/10.1371/journal.ppat.1004060openalex-snapshot
A Neutralizing Anti-gH/gL Monoclonal Antibody Is Protective in the Guinea Pig Model of Congenital CMV Infection
inferredcites →https://doi.org/10.21873/anticanres.11483openalex-snapshot
Acute Graft Versus Host Disease: A Comprehensive Review
inferredcites →https://doi.org/10.3109/07357907.2014.919301openalex-snapshot
Complications of Allogeneic Hematopoietic Stem Cell Transplantation

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3800383openalex-extracted
Novel Potent Neutralizing Antibodies Revealed the Domain I of HCMV Glycoprotein B for Vaccine Design
inferred← citeshttps://doi.org/10.1016/b978-0-12-814515-9.00114-4openalex-snapshot
Use of Immunoglobulins in the Prevention of Viral Infections
inferred← citeshttps://doi.org/10.1016/j.antiviral.2024.105902openalex-snapshot
New technologies in therapeutic antibody development: The next frontier for treating infectious diseases
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.115646openalex-snapshot
Structural basis of human cytomegalovirus neutralization by gB AD-5-specific potent antibodies
inferred← citeshttps://doi.org/10.1016/j.coviro.2021.12.002openalex-snapshot
Recent progress in development of monoclonal antibodies against human cytomegalovirus
inferred← citeshttps://doi.org/10.1016/j.drudis.2023.103833openalex-snapshot
Ligands and receptors in human cytomegalovirus entry: Current therapies and new directions
inferred← citeshttps://doi.org/10.1016/j.immuni.2023.10.009openalex-snapshot
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer
inferred← citeshttps://doi.org/10.1016/j.tim.2022.12.003openalex-snapshot
Novel monoclonal antibody-based therapies: implications for the treatment and prevention of HCMV disease
inferred← citeshttps://doi.org/10.1016/j.tim.2023.03.001openalex-snapshot
Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents
inferred← citeshttps://doi.org/10.1016/s1473-3099(25)00345-7openalex-snapshot
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
inferred← citeshttps://doi.org/10.1038/s41573-022-00495-3openalex-snapshot
Antibodies to combat viral infections: development strategies and progress
inferred← citeshttps://doi.org/10.1038/s42003-022-03294-zopenalex-snapshot
Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH
inferred← citeshttps://doi.org/10.1080/14728222.2023.2193330openalex-snapshot
Myocarditis: causes, mechanisms, and evolving therapies
inferred← citeshttps://doi.org/10.1089/mab.2021.0004openalex-snapshot
Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond
inferred← citeshttps://doi.org/10.1128/aac.02422-20openalex-snapshot
Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus
inferred← citeshttps://doi.org/10.1128/cmr.00043-19openalex-snapshot
Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation
inferred← citeshttps://doi.org/10.1128/jvi.00325-26openalex-snapshot
Mapping the monoclonal antibody landscape of human cytomegalovirus
inferred← citeshttps://doi.org/10.1128/jvi.00879-26openalex-snapshot
Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations
inferred← citeshttps://doi.org/10.1172/jci139296openalex-snapshot
Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus
inferred← citeshttps://doi.org/10.1186/s12967-025-06815-6openalex-snapshot
T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus
inferred← citeshttps://doi.org/10.1371/journal.pone.0285672openalex-snapshot
A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B
inferred← citeshttps://doi.org/10.1371/journal.ppat.1009471openalex-snapshot
Targeted mutagenesis on PDGFRα-Fc identifies amino acid modifications that allow efficient inhibition of HCMV infection while abolishing PDGF sequestration
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1827628openalex-snapshot
Progress and prospects for herpesvirus vaccination using gB antigens
inferred← citeshttps://doi.org/10.3389/fmicb.2023.1321116openalex-snapshot
Anti-CMV therapy, what next? A systematic review
inferred← citeshttps://doi.org/10.3390/cells13010020openalex-snapshot
Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice
inferred← citeshttps://doi.org/10.3390/ijms22168728openalex-snapshot
Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection
inferred← citeshttps://doi.org/10.3390/ijms24054417openalex-snapshot
Fibroblast, Epithelial and Endothelial Cell-Derived Human Cytomegalovirus Strains Display Distinct Neutralizing Antibody Responses and Varying Levels of gH/gL Complexes
inferred← citeshttps://doi.org/10.3390/microorganisms11102372openalex-snapshot
Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies
inferred← citeshttps://doi.org/10.3390/microorganisms12071355openalex-snapshot
Evaluation of the In Vitro Capacity of Anti-Human Cytomegalovirus Antibodies to Initiate Antibody-Dependent Cell Cytotoxicity
inferred← citeshttps://doi.org/10.3390/pathogens14070629openalex-snapshot
Human Cytomegalovirus Immune Evasion of Natural Killer Cells: A Virus for All Seasons?
inferred← citeshttps://doi.org/10.3390/pharmaceutics15051538openalex-snapshot
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
inferred← citeshttps://doi.org/10.3390/v14020284openalex-snapshot
Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts
inferred← citeshttps://doi.org/10.3390/v16081268openalex-snapshot
Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation
inferred← citeshttps://doi.org/10.3390/v17070936openalex-snapshot
Recent Progress in the Vaccine Development Against Epstein–Barr Virus
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.